Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In 2019, the US FDA approved bremelanotide subcutaneous injection (Vyleesi, AMAG Pharmaceuticals) for the treatment of acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women making it only the second approved pharmacotherapy for female sexual dysfunction and the first melanocortin-based medicine to reach clinical approval
To view a copy of this licence, visit About this article Cite this article Uboveja, A., Yang, B., Buj, R
Pharmacology Biochemistry and Behavior , 15(5), 717722
Intravenous administration bypasses bioavailability constraints but requires clinical administration and cost consideration
Some clients choose periodic treatments for ongoing antioxidant support
US$ 20.03
US$ 22.45
US$ 27.63
US$ 22.52
